Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase
Authors:
- Christopher R. LaPenseeCLChristopher R. LaPensee
- El Mustapha BahassiEBEl Mustapha Bahassi
- Nira Ben-JonathanNBNira Ben-Jonathan
Open Access
- 14 May 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 30 (8) , 1298-1304
Abstract
Resistance to chemotherapy is a major obstacle for successful treatment of breast cancer patients. Given that prolactin (PRL) acts as an anti-apoptotic/survival factor in the breast, we postulated that it antagonizes cytotoxicity by chemotherapeutic drugs. Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin. PRL prevented cisplatin-induced G 2 /M cell cycle arrest and apoptosis. In the presence of PRL, significantly less cisplatin was bound to DNA, as determined by mass spectroscopy, and little DNA damage was seen by γ-H2AX staining. PRL dramatically increased the activity of glutathione- S -transferase (GST), which sequesters cisplatin in the cytoplasm; this increase was abrogated by Jak and mitogen-activated protein kinase inhibitors. PRL upregulated the expression of the GSTμ, but not the π, isozyme. A GST inhibitor abrogated antagonism of cisplatin cytotoxicity by PRL. In conclusion, PRL confers resistance against cisplatin by activating a detoxification enzyme, thereby reducing drug entry into the nucleus. These data provide a rational explanation for the ineffectiveness of cisplatin in breast cancer, which is characterized by high expression of both PRL and its receptor. Suppression of PRL production or blockade of its actions should benefit patients undergoing chemotherapy by allowing for lower drug doses and expanded drug options.Keywords
This publication has 44 references indexed in Scilit:
- Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicityBreast Cancer Research, 2008
- What Can We Learn from Rodents about Prolactin in Humans?Endocrine Reviews, 2007
- Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA bindingNeuroToxicology, 2006
- Histone H2A phosphorylation in DNA double‐strand break repairThe FEBS Journal, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicityNeurobiology of Disease, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129ROncogene, 2002
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- ProlactinPharmacology & Therapeutics, 1998